Visit our Evidence-Based Covid-19 Website and Stay Up to Date with the latest Research.
Author Verified
ACE Report #5931
Ace Report Cover Metabolic Disorders

Prostate cancer: Zoledronic acid as an adjuvant therapy is well-tolerated and improves BMD

Study Type:Therapy
OE Level Evidence:2
Journal Level of Evidence:N/A

RTOG 0518: randomized phase III trial to evaluate zoledronic acid for prevention of osteoporosis and associated fractures in prostate cancer patients

Prostate Cancer Prostatic Dis. 2013 Dec;16(4):382-6. doi: 10.1038/pcan.2013.35. Epub 2013 Oct 1

Contributing Authors: LA Kachnic SL Pugh P Tai M Smith E Gore AB Shah AG Martin HE Kim A Nabid CA Lawton

Did you know you're eligible to earn 0.5 CME credits for reading this report? Click Here


109 patients with nonmetastatic prostate cancer, undergoing androgen deprivation therapy (ADT) in combination with radiotherapy (RT), were randomized to receive a 4-mg infusion of zoledronic acid every 6 months for 3 years, as well as vitamin D and calcium supplements, or supplements alone. The purpose of this study was to examine the safety and efficacy of zoledronic acid with respect to the inci...

CME Image

Continuing Medical Education Credits

You could be earning 0.5 CME credits for each report you read.


Please Login or Join to leave comments.